

While Applicant does not admit that the amendments are necessary in light of the teachings of the application, the amendments are submitted in order to expedite prosecution of the application. Applicant contends that in light of the amendments, the rejections are overcome, and the application is now in condition for allowance. Further, Applicant reserves the right to argue for additional claims of a scope as broad, or broader, than that of the claims previously rejected in continuing applications.

**D. Conclusion**

In view of the above, it is respectfully submitted that the present application is in condition for allowance.

The Examiner is invited to contact the undersigned attorney at 512-536-3035 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,

 *for*

Reg. No. 45,104

Mark B. Wilson  
Reg. No. 37,259  
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
512.536.3035

Date: March 29, 2001

C

**APPENDIX A**  
**Claim Amendments**

1. (Thrice Amended) A method for inhibiting cancer cell growth or killing cancer cells comprising eliciting [an antigen] a lipid specific [immune] antibody response with an immunologically effective amount of a composition comprising a phosphatidylserine /polypeptide conjugate.
7. (Twice Amended) The method of claim 1, wherein said [immune] lipid specific antibody response is elicited with phosphatidylserine/polypeptide conjugate comprising a polypeptide selected from the group consisting of BSA, KLH, BGG, diphtheria toxin, and  $\beta$ 2-glycoprotein I.
11. (Canceled) [The method of claim 8, wherein said lipid is phosphatidylcholine or phosphatidylserine.]
12. (Twice Amended) A method of generating [an antigen] a lipid specific [immune] antibody response, comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylserine/polypeptide conjugate composition.
28. (Canceled) [The method of claim 1, wherein said lipid or lipid/polypeptide conjugate is phosphatidylserine or a phosphatidylserine/polypeptide conjugate.]
43. (Amended) The method of claim 12, wherein said [immune] lipid specific antibody response is elicited with a phosphatidylserine/polypeptide conjugate comprising a polypeptide selected from the group consisting of BSA, KLH, BGG, diphtheria toxin, and  $\beta$ 2-glycoprotein I.